KG&L Capital Management LLC Buys 1,255 Shares of GlaxoSmithKline plc (NYSE:GSK)

KG&L Capital Management LLC raised its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 24.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,448 shares of the pharmaceutical company’s stock after acquiring an additional 1,255 shares during the quarter. KG&L Capital Management LLC’s holdings in GlaxoSmithKline were worth $275,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Juncture Wealth Strategies LLC boosted its position in GlaxoSmithKline by 37.9% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 8,000 shares of the pharmaceutical company’s stock valued at $341,000 after acquiring an additional 2,200 shares in the last quarter. Pacer Advisors Inc. boosted its position in GlaxoSmithKline by 4.9% during the 3rd quarter. Pacer Advisors Inc. now owns 117,244 shares of the pharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 5,500 shares in the last quarter. We Are One Seven LLC boosted its position in GlaxoSmithKline by 7.3% during the 3rd quarter. We Are One Seven LLC now owns 6,660 shares of the pharmaceutical company’s stock valued at $284,000 after acquiring an additional 455 shares in the last quarter. Gradient Investments LLC boosted its position in GlaxoSmithKline by 192.6% during the 3rd quarter. Gradient Investments LLC now owns 1,226 shares of the pharmaceutical company’s stock valued at $52,000 after acquiring an additional 807 shares in the last quarter. Finally, Gofen & Glossberg LLC IL boosted its position in GlaxoSmithKline by 0.9% during the 3rd quarter. Gofen & Glossberg LLC IL now owns 27,908 shares of the pharmaceutical company’s stock valued at $1,191,000 after acquiring an additional 260 shares in the last quarter. 11.12% of the stock is currently owned by institutional investors and hedge funds.

Several analysts have issued reports on the company. ValuEngine cut GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Tuesday, September 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, August 29th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, August 13th. Cantor Fitzgerald raised GlaxoSmithKline from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Societe Generale upgraded GlaxoSmithKline from a “sell” rating to a “buy” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $41.79.



Shares of GSK traded down $0.07 during midday trading on Friday, hitting $42.18. 2,971,533 shares of the company’s stock traded hands, compared to its average volume of 2,221,049. GlaxoSmithKline plc has a 1 year low of $36.41 and a 1 year high of $43.22. The firm’s fifty day moving average is $41.64 and its 200-day moving average is $40.76. The company has a current ratio of 0.71, a quick ratio of 0.48 and a debt-to-equity ratio of 7.86. The stock has a market capitalization of $104.46 billion, a price-to-earnings ratio of 13.35, a price-to-earnings-growth ratio of 2.01 and a beta of 0.68.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 24th. The pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.64 by $0.14. GlaxoSmithKline had a return on equity of 175.45% and a net margin of 13.84%. The firm had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. On average, equities research analysts anticipate that GlaxoSmithKline plc will post 2.96 EPS for the current year.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline acquired 177,777 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average price of $45.00 per share, for a total transaction of $7,999,965.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GlaxoSmithKline Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: What is a portfolio manager?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.